Clinical Trial Search

Primary: Frequency of Ocular Adverse Events, Systemic Adverse Events, Serious, and Treatment-emergent Non-serious Adverse Events — 10; 8; 3; 5 Participants

Primary: Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease. — 142; 69; 22; 131 Participants

Primary: Overall Success — 318; 260 Participants

Primary: Days Alive and Out of Hospital — 26.9; 25.4 Days Alive and Out of Hospital

Primary: Left Ventricular Global Longitudinal Strain (LVGLS) — 16.6; 16.4 % of LVGLS

Primary: Number of Participants Recruited — 5; 5 Participants

Primary: Number of Participants With Adverse Events — 45; 47 Participants

Primary: Patient Health Questionnaire-9 — 6.66; 7.33; 7.89; 7.84 score on a scale — p=<0.0001

Primary: Composite Safety Endpoint;Proportion of MITT Subjects With One or More of the Specified Device or Procedure Related SAEs — 6; 4 Participants

Primary: Peripheral Markers of Inflammation — 17.09; 20.22; 14.79; 11.78 pg/ml

Primary: 24 Hour Opioid Consumption — 51; 55; 27; 32 mg oral morphine equivalents (OMEs)

Primary: 9 Month In-stent Late Loss — 0.11; 0.40 percentage of Intent-to-treat patients — p=0.05

Primary: Subject-Reported Ocular Itching Score Assessed Over 110 to 210 Minutes in the Allergy Chamber — 0.94; 1.38 score on a scale

Primary: Safety: Toxicity Symptoms Graded According to CTCAE v4.03. — 61; 139; 411; 7 Number of Events

Primary: Overall Response Rate (ORR) - Best Overall Response — 0; 0; 1; 0 Participants